Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center

Alejandro Mejia, Alan Norman Langnas, Byers W. Shaw, Clarivet Torres, Debra L. Sudan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Hepatoblastoma (HB) is the most common malignant liver tumor in children. The application of living donor liver transplantation (LDLT) in the management of unresectable HB may add new therapeutic opportunities. We evaluated the outcomes of patients who underwent liver transplantation for treatment of unresectable HB in the period between August 1985 and June 2003. Ten children had a diagnosis of unresectable HB. Mean age at transplantation was 5.8 yr. Eight patients were transplanted with deceased donor grafts. Two patients underwent LDLT. Pre-transplant chemotherapy was used in 90% of cases. Post-transplant survival ranges from 3.7 to 18.6 yr. Three patients died of recurrent disease at 4, 14 and 38 months. The two LDLT recipients were able to get pre-transplant chemotherapy with a rapid decision towards transplantation; both are alive and well at 5.5 and 11 yr post-transplant. Our experience supports the role of LDLT and deceased donor liver transplantation in the management of unresectable HB when waiting times can be detrimental to the patient's survival.

Original languageEnglish (US)
Pages (from-to)721-725
Number of pages5
JournalClinical Transplantation
Volume19
Issue number6
DOIs
StatePublished - Dec 1 2005

Fingerprint

Hepatoblastoma
Living Donors
Liver Transplantation
Transplants
Transplantation
Tissue Donors
Drug Therapy
Survival
Liver
Therapeutics
Neoplasms

Keywords

  • Hepatoblastoma
  • Living donor
  • Pediatric
  • Transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center. / Mejia, Alejandro; Langnas, Alan Norman; Shaw, Byers W.; Torres, Clarivet; Sudan, Debra L.

In: Clinical Transplantation, Vol. 19, No. 6, 01.12.2005, p. 721-725.

Research output: Contribution to journalArticle

Mejia, Alejandro ; Langnas, Alan Norman ; Shaw, Byers W. ; Torres, Clarivet ; Sudan, Debra L. / Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center. In: Clinical Transplantation. 2005 ; Vol. 19, No. 6. pp. 721-725.
@article{24d9d7b157bb487f90bd5d1b68eecc27,
title = "Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center",
abstract = "Hepatoblastoma (HB) is the most common malignant liver tumor in children. The application of living donor liver transplantation (LDLT) in the management of unresectable HB may add new therapeutic opportunities. We evaluated the outcomes of patients who underwent liver transplantation for treatment of unresectable HB in the period between August 1985 and June 2003. Ten children had a diagnosis of unresectable HB. Mean age at transplantation was 5.8 yr. Eight patients were transplanted with deceased donor grafts. Two patients underwent LDLT. Pre-transplant chemotherapy was used in 90{\%} of cases. Post-transplant survival ranges from 3.7 to 18.6 yr. Three patients died of recurrent disease at 4, 14 and 38 months. The two LDLT recipients were able to get pre-transplant chemotherapy with a rapid decision towards transplantation; both are alive and well at 5.5 and 11 yr post-transplant. Our experience supports the role of LDLT and deceased donor liver transplantation in the management of unresectable HB when waiting times can be detrimental to the patient's survival.",
keywords = "Hepatoblastoma, Living donor, Pediatric, Transplantation",
author = "Alejandro Mejia and Langnas, {Alan Norman} and Shaw, {Byers W.} and Clarivet Torres and Sudan, {Debra L.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1111/j.1399-0012.2005.00410.x",
language = "English (US)",
volume = "19",
pages = "721--725",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center

AU - Mejia, Alejandro

AU - Langnas, Alan Norman

AU - Shaw, Byers W.

AU - Torres, Clarivet

AU - Sudan, Debra L.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Hepatoblastoma (HB) is the most common malignant liver tumor in children. The application of living donor liver transplantation (LDLT) in the management of unresectable HB may add new therapeutic opportunities. We evaluated the outcomes of patients who underwent liver transplantation for treatment of unresectable HB in the period between August 1985 and June 2003. Ten children had a diagnosis of unresectable HB. Mean age at transplantation was 5.8 yr. Eight patients were transplanted with deceased donor grafts. Two patients underwent LDLT. Pre-transplant chemotherapy was used in 90% of cases. Post-transplant survival ranges from 3.7 to 18.6 yr. Three patients died of recurrent disease at 4, 14 and 38 months. The two LDLT recipients were able to get pre-transplant chemotherapy with a rapid decision towards transplantation; both are alive and well at 5.5 and 11 yr post-transplant. Our experience supports the role of LDLT and deceased donor liver transplantation in the management of unresectable HB when waiting times can be detrimental to the patient's survival.

AB - Hepatoblastoma (HB) is the most common malignant liver tumor in children. The application of living donor liver transplantation (LDLT) in the management of unresectable HB may add new therapeutic opportunities. We evaluated the outcomes of patients who underwent liver transplantation for treatment of unresectable HB in the period between August 1985 and June 2003. Ten children had a diagnosis of unresectable HB. Mean age at transplantation was 5.8 yr. Eight patients were transplanted with deceased donor grafts. Two patients underwent LDLT. Pre-transplant chemotherapy was used in 90% of cases. Post-transplant survival ranges from 3.7 to 18.6 yr. Three patients died of recurrent disease at 4, 14 and 38 months. The two LDLT recipients were able to get pre-transplant chemotherapy with a rapid decision towards transplantation; both are alive and well at 5.5 and 11 yr post-transplant. Our experience supports the role of LDLT and deceased donor liver transplantation in the management of unresectable HB when waiting times can be detrimental to the patient's survival.

KW - Hepatoblastoma

KW - Living donor

KW - Pediatric

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=28644448726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644448726&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2005.00410.x

DO - 10.1111/j.1399-0012.2005.00410.x

M3 - Article

C2 - 16313316

AN - SCOPUS:28644448726

VL - 19

SP - 721

EP - 725

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -